Newsletter | Things to know before investing in the EV sector; Tech giants hiring H1 workers after layoffs & more-March 2024-www.financetom.com

Newsletter | Things to know before investing in the EV sector; Tech giants hiring H1 workers after layoffs & more

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Newsletter | Things to know before investing in the EV sector; Tech giants hiring H1 workers after layoffs & more

May 19, 2023 3:59 AM

Here's a rundown of 11 significant news stories to keep you in the know:

Share Market Live

NSE

#ExpertEdge

Previous page： Moderna to Collaborate With OpenAI to Launch New Generation of Medicines Next page： Bank of America shareholders reject proposal to split CEO, chair roles

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Moderna to Collaborate With OpenAI to Launch New Generation of Medicines

Apr 24, 2024

11:36 AM EDT, 04/24/2024 (MT Newswires) -- Moderna ( MRNA ) and OpenAI said Wednesday they will continue to collaborate to launch a new generation of medicines. The drugmaker and Microsoft ( MSFT )-backed (MSFT) OpenAI started their collaboration in early 2023 with the launch of Moderna's ( MRNA ) own instance of ChatGPT, called mChat. Moderna ( MRNA )...

Bank of America shareholders reject proposal to split CEO, chair roles

Apr 24, 2024

NEW YORK, April 24 (Reuters) - Bank of America ( BAC ) shareholders rejected a proposal to divide the CEO and chairman roles held by Brian Moynihan on Wednesday at the company's virtual annual meeting. Proxy advisers had recommend investors vote for the bank to separate the positions in an effort to improve governance. The proposal was backed by 31%...

Ascendis Pharma Gets UK Regulator's Approval for Yorvipath to Treat Hypoparathyroidism

Apr 24, 2024

11:33 AM EDT, 04/24/2024 (MT Newswires) -- Ascendis Pharma ( ASND ) said Wednesday that the UK's Medicines and Healthcare Products Regulatory Agency has granted marketing authorization for Yorvipath as a parathyroid hormone, or PTH, replacement therapy to treat adults with chronic hypoparathyroidism. The UK regulator also granted orphan drug status to Yorvipath, or palopegteriparatide, providing 10 years of market...

--McKesson Keeps Quarterly Dividend at $0.62 Per Share; Payable July 1 to Shareholders of Record on June 3

Apr 24, 2024

11:30 AM EDT, 04/24/2024 (MT Newswires) -- Price: 530.68, Change: -1.32, Percent Change: -0.25 ...